ObjectiveTo examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS).MethodsIn the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 years or diagnosis of clinically definite MS (CDMS), all patients were offered open-label IFNB1b treatment for a maximum duration of 5 years. Thereafter, patients were enrolled in an observational extension study for up to 8.7 years.ResultsOf the initial 468 patients, 284 (60.7%; IFNB1b: 178 (61.0% of the original arm), placebo: 106 (60.2% of original arm)) were enrolled in the extension study. 94.2% of patients were receiving IFNB1b. Patients originally randomised to IFNB1b had a reduced risk of developing CDMS by 32.2% over the 8-year observation period (HR 0.678; 95% CI 0.525 to 0.875; p=0.0030), a longer median time to CDMS by 1345 days (95% CI 389 to 2301), and a lower annualised relapse rate (0.196 (95% CI 0.176 to 0.218) versus 0.255 (95% CI 0.226 to 0.287), p=0.0012), with differences mainly emerging in the first year of the study. Cognitive outcomes remained higher in the early treated patients. EDSS remained low over time with a median of 1.5 in both arms.ConclusionsThese 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Introduction
Better understanding how hospital staff members (HSMs), including HCWs, were contaminated by SARS-CoV-2 during the first wave can help refining the control measures, in the context of the current second wave in Europe.
Methods
From March 5
th
to May 10
th
2020, the infectious diseases unit at Raymond-Poincaré teaching Hospital opened a weekday consultation dedicated to HSMs for a PCR testing. While in the waiting room, HSMs were offered to complete a questionnaire on their potential risk exposure to SARS-CoV-2.
Results
Of the 200 HSMs screened, 70 were positive. Ninety-nine HSMs (including 86 HCWs) completed the questionnaire of whom 28 cases positive. In the multivariable analysis among healthcare workers, age ≥ 44 years-old (aOR = 5.2, 95%CI [1.4-22.5]), not using a facemask systematically when caring for a patient (aOR = 13.9, 95%CI [1.8-293.0]), were significantly associated with SARS-CoV-2 infection. Conversely, working in a ward dedicated to COVID-19 patients (aOR = 0.7, 95%CI [0.2-3.2]) was not significantly associated with SARS-CoV-2 infection. Regarding community related exposures occurring in and outside the hospital among the HSMs, participation to meetings inside the hospital without wearing a facemask (aOR = 21.3, 95%CI [4.5-143.9]) and participation to private gathering (aOR = 10, 95%CI [1.3-91.0]) were significantly associated with SARS-CoV-2 infection.
Conclusions
Our results support the effectiveness of barrier precautions, underline that in-hospital contaminations not related to patient care may occur, and that part of the contaminations may be related to exposures in the community. Better protecting HCWs against COVID-19 and thereby ensuring workforces is crucial to fight the current second wave of the epidemic.
Electronically recorded CPIs inform on the risk of MRSA carriage, warranting more study of in-hospital contact networks to design targeted intervention strategies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.